Prevention, Treatment, and Management

  • FDA Gives Updates on Newly Approved Agents for Rheumatic Diseases

    FDA Gives Updates on Newly Approved Agents for Rheumatic Diseases

    Jeong Min Yu, MD, MS, and other medical officers from the U.S. Food and Drug Administration discussed approvals including a Janus kinase and tyrosine kinase 2 inhibitor for dermatomyositis and an interleukin-23 antagonist for psoriatic arthritis, both for the treatment of adults.

  • Hormone Therapy During Menopause Could Have a Role for Some Patients with Rheumatic Diseases

    Hormone Therapy During Menopause Could Have a Role for Some Patients with Rheumatic Diseases

    Stephanie Faubion, MD, MBA, and Karen Costenbader, MD, MPH, reviewed new evidence about the value of hormone therapy for patients with autoimmune disease in menopause and post menopause.

  • Partnership Between Physical Therapists, Rheumatologists Improves Patient Care

    Partnership Between Physical Therapists, Rheumatologists Improves Patient Care

    Laura Passalent, BSc, PT, MHS, and other experienced clinicians will explain how such collaboration can streamline access to care, open up provider schedules, and give people living with rheumatic disease more control over their lives.

  • Experts to Elaborate on Role of GLP-1 RAs in Rheumatology, Including Weight-Independent Benefits

    Experts to Elaborate on Role of GLP-1 RAs in Rheumatology, Including Weight-Independent Benefits

    Michael Weintraub, MD, and Veena K. Ranganath, MD, MS, RhMSUS, will discuss the evolving landscape of glucagon-like peptide-1 receptor agonists and current evidence for the use of this kind of incretin therapy in rheumatologic diseases.

  • Immunology Bootcamp Series Offers Foundational Insights for Trainees

    Immunology Bootcamp Series Offers Foundational Insights for Trainees

    In two lectures across two days, Varitka Kesarwani, MBBS, will review the mechanisms of immunology to help attendees build a mental framework they can leverage in the clinic.

  • Three-Day Series to Examine the Latest Developments in Cellular Immunotherapy for Rheumatic Disease

    Three-Day Series to Examine the Latest Developments in Cellular Immunotherapy for Rheumatic Disease

    Experts will provide an overview of the immunobiology of cellular therapies for rheumatic diseases, examine which diseases might be most responsive to these therapies, share results from recent clinical trials, and debate the correct pace for the widespread use of cellular therapy in rheumatology.